Monitor the investigation for the ALJ's initial determination on infringement and validity, expected within 15-18 months. A finding of violation could lead to an exclusion order affecting Beckman Coulter's spectral flow cytometry products, which are part of Danaher's life sciences portfolio.
Price Chart
Executive Summary
The USITC instituted Investigation No. 337-TA-1528 against Beckman Coulter, Inc. (a wholly-owned subsidiary of Danaher Corporation) and its affiliate, based on a complaint by Cytek Biosciences alleging infringement of three patents related to spectral flow cytometry systems. The investigation covers Beckman Coulter's mosaic 88 and mosaic 63 products. This is an early-stage proceeding with no findings yet, so the outcome is uncertain.
ITC Section 337 Details
Key Facts
- Investigation No. 337-TA-1528 instituted on November 10, 2026, regarding certain spectral flow cytometry systems and components.
- Complainant: Cytek Biosciences, Inc. (CTKB). Respondents: Beckman Coulter, Inc. and Beckman Coulter Biotechnology (Suzhou) Co., Ltd.
- Beckman Coulter, Inc. is a wholly-owned subsidiary of Danaher Corporation (DHR).
- Accused products include Beckman Coulter's mosaic 88 and mosaic 63 products.
- Patents at issue: U.S. Patent Nos. 12,754,128; 12,487,167; and 10,739,245.
- Complainant requests a limited exclusion order and cease and desist orders.
- Responses from respondents are due within 20 days of service of the complaint and notice.
Financial Impact
Not quantifiable at this stage; no findings or remedies have been issued.
Risk Factors
- If a violation is found, a limited exclusion order could block importation of Beckman Coulter's mosaic 88 and mosaic 63 products into the U.S.
- The investigation is at an early stage; no substantive rulings have been made.
- Danaher's overall revenue exposure from these specific products is not disclosed in the notice.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 USITC notice.
| Document | Accession Number |
|---|---|
| ITC-337 Data (Synthetic) | itc-2026-23254-DHR |
Track record
27 reports on DHR
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +24.48% at T+60 after the Jul 21, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 20261d ago ITC Section 337 Neutral 3/10 Viewing Entry price pending
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $235.31 Now $229.91 −2.29% settles Nov 18
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $235.31 Now $229.91 −2.29% settles Nov 18
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $236.11 Now $229.91 −2.63% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $236.11 Now $229.91 −2.63% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $235.12 to $229.91 Now $229.91 −2.22% ▼ −2.22% −0.52% vs SPY
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $226.34 to $232.16 Now $229.91 +1.58% ▲ +2.57% −0.72% vs SPY
- Oct 29, 202618d ago Insider Cluster Neutral 2/10 Entry $232.23 to $230.25 Now $229.91 −1.00% ▼ −0.85% +1.85% vs SPY
- Oct 29, 202618d ago Insider Cluster Neutral 3/10 Entry $232.23 to $230.25 Now $229.91 −1.00% ▼ −0.85% +1.85% vs SPY
- Oct 28, 202619d ago 144 Neutral 3/10 Entry $234.07 to $234.93 Now $229.91 −1.78% ▲ +0.37% +1.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time ITC Section 337 Intelligence
Market-moving USITC Section 337 notices analyzed within minutes. Complaints, exclusion orders, final determinations, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers